{"id":3139,"date":"2013-11-08T16:15:59","date_gmt":"2013-11-08T16:15:59","guid":{"rendered":"\/?p=3139"},"modified":"2013-11-08T16:17:56","modified_gmt":"2013-11-08T16:17:56","slug":"ap-pharma-inc-otcbbappa-runs-up-in-expectation-of-financial-results","status":"publish","type":"post","link":"\/articles\/ap-pharma-inc-otcbbappa-runs-up-in-expectation-of-financial-results\/","title":{"rendered":"AP Pharma, Inc. (OTCBB:APPA) Runs Up in Expectation of Financial Results"},"content":{"rendered":"

AP Pharma, Inc. (OTCBB:APPA<\/a>) is a high-loyalty pharmaceutical ticker that is inching toward a border price, 50 cents. On Thursday’s short hour of trading, APPA<\/a> reached 47 cents, adding a tentative 1% to the price, on dollar volumes a bit below $500,000. APPA<\/a> is on track to close a gap from the summer months, when it failed to deliver the expectations of investors. Now, APPA<\/a> is heading toward a new round of financial announcements, and this usually provides a few good days of trading. \"APPA1108.png\" <\/p>\n

APPA<\/a> was inflated beyond proportion by a promotion in March, and swung up and down in the summer months between 30 and 50 cents. Now, the company came in with a small change to its management, adding Paul Marshall as senior vice president, and Brian Drazba as vice-president of finance. \"APPA1108.png\"<\/p>\n

Unfortunately, APPA<\/a> still has not managed to complete its promise to list to a higher-tier exchange. But if this happens, the shares may expect a serious boost. APPA<\/a> still does not even have a date for the second submission of NASDAQ documentation- and this also means another press release in the making, potentially riling up investors.<\/p>\n

Otherwise, APPA<\/a> continues to be burdened by the usual challenges of an ambitious pharmaceutical developer:<\/p>\n